Stay updated on OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.

Latest updates to the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedThe page footer now shows a newer ClinicalTrials.gov release revision identifier (“v3.5.3” instead of “v3.5.2”). This reflects a site/version update rather than a substantive change to the study details.SummaryDifference0.1%

- Check10 days agoChange DetectedFooter revision label changed from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedFooter revision label updated from v3.4.3 to v3.5.0. No study details or user-facing content are affected.SummaryDifference0.1%

- Check46 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check74 days agoChange DetectedThe update adds Revision: v3.4.2 and removes the prior government funding/operating status notices; overall study content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check81 days agoChange DetectedA site-wide notice about government funding status and NIH operating status was added, and the page version was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.